Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Reports Adverse Effects from Vaccine Limited to One Case

publication date: Dec 2, 2008

Sinovac Biotech Ltd. (京科兴生物制品有限公司) released a statement clarifying the situation regarding the suspension of its most important product, the hepatitis A vaccine Healive®. The company said the Health Services Bureau of Fengtai District in Beijing suspended the use of just 83 doses of the drug. The action came after the death of a minor who had been treated with the vaccine two days previously. The company said no other adverse reactions have been reported thus far. More details...

Stock Symbol: (NYSE Alternext: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here